(VKTX) Viking Therapeutics - Overview

Sector: HealthcareIndustry: Biotechnology | Exchange NASDAQ (USA) | Currency USD | Market Cap: 3.736m | Total Return 24.5% in 12m

Stock: Metabolic Therapies, Endocrine Therapies, Drug Candidates

Total Rating 28
Risk 81
Buy Signal -1.46
Biotechnology +1.0
Biotechnology +1.4
Market Cap: 3,736m
Avg Trading Vol: 74.0M USD
ATR: 5.42%
Peers RS (IBD): 22.8
Risk 5d forecast
Volatility 84.9%
Relative Tail Risk -19.2%
Reward TTM
Sharpe Ratio 0.66
Alpha 3.18
Character TTM
Beta 1.875
Beta Downside 0.805
Drawdowns 3y
Max DD 78.86%
CAGR/Max DD 0.32

EPS (Earnings per Share)

EPS (Earnings per Share) of VKTX over the last years for every Quarter: "2021-03": -0.19, "2021-06": -0.2, "2021-09": -0.17, "2021-12": -0.16, "2022-03": -0.21, "2022-06": -0.23, "2022-09": -0.21, "2022-12": -0.26, "2023-03": -0.25, "2023-06": -0.19, "2023-09": -0.23, "2023-12": -0.25, "2024-03": -0.26, "2024-06": -0.2, "2024-09": -0.22, "2024-12": -0.32, "2025-03": -0.41, "2025-06": -0.58, "2025-09": -0.81, "2025-12": -1.38,
EPS CAGR: -64.34%
EPS Trend: -71.5%
Last SUE: -4.00
Qual. Beats: 0

Revenue

Revenue of VKTX over the last years for every Quarter: 2021-03: 2.69E-6, 2021-06: 0.002737, 2021-09: 0.002608, 2021-12: 1.07E-5, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 0.436, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0, 2025-06: 0, 2025-09: 0, 2025-12: 0,
Rev. CAGR: 0.00%
Rev. Trend: -2.8%
Last SUE: 0.00
Qual. Beats: 0

Risks

Technicals: volatile

Description: VKTX Viking Therapeutics March 05, 2026

Viking Therapeutics, Inc. (VKTX) is a clinical-stage biopharmaceutical company. It specializes in developing new treatments for metabolic and endocrine disorders, a sector characterized by high research and development costs and lengthy drug approval processes.

The companys primary drug candidate, VK2809, is currently in Phase IIb clinical trials for non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). Other pipeline assets include VK5211, a selective androgen receptor modulator in Phase II for hip fracture recovery, and VK0612, also in Phase II for metabolic disorders. Earlier-stage candidates include VK2735, a dual agonist in Phase I, and VK0214, targeting X-linked adrenoleukodystrophy.

Viking Therapeutics, founded in 2012, operates within the biotechnology business model, which typically involves developing intellectual property around novel compounds and seeking regulatory approval for commercialization.

For more detailed financial and operational data, consider exploring its profile on ValueRay.

Headlines to watch out for

  • VK2809 Phase 2b NASH trial results impact stock
  • VK2735 clinical trial progress drives investor sentiment
  • Regulatory approval for lead drug candidates crucial
  • Competition in metabolic disorder therapies affects market share

Piotroski VR‑10 (Strict, 0-10) 0.0

Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.39 > 0.02 and ΔFCF/TA -29.27 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.39 > 3% & CFO -278.7m > Net Income -359.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 9.33 > 1.5 & < 3
Outstanding Shares: last quarter (114.0m) vs 12m ago 2.39% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%)
Interest Coverage Ratio: -7.03k > 6 (EBITDA TTM -393.0m / Interest Expense TTM 56.0k)

Altman Z'' -12.86

A: 0.89 (Total Current Assets 715.6m - Total Current Liabilities 76.7m) / Total Assets 715.7m
B: -1.18 (Retained Earnings -847.5m / Total Assets 715.7m)
C: -0.48 (EBIT TTM -393.4m / Avg Total Assets 812.0m)
D: -11.05 (Book Value of Equity -847.2m / Total Liabilities 76.7m)
Altman-Z'' Score: -12.86 = D

Beneish M

DSRI: none (Receivables none/none, Revenue 0.0/0.0)
GMI: 1.00 (fallback, negative margins)
AQI: 0.57 (AQ_t 0.00 / AQ_t-1 0.00)
SGI: none (Revenue 0.0 / 0.0)
TATA: -0.11 (NI -359.6m - CFO -278.7m) / TA 715.7m)
Beneish M-Score: cannot calculate (missing components)

What is the price of VKTX shares?

As of March 29, 2026, the stock is trading at USD 32.52 with a total of 2,244,820 shares traded.
Over the past week, the price has changed by +0.59%, over one month by -3.90%, over three months by -10.81% and over the past year by +24.45%.

Is VKTX a buy, sell or hold?

Viking Therapeutics has received a consensus analysts rating of 4.42. Therefore, it is recommended to buy VKTX.
  • StrongBuy: 10
  • Buy: 7
  • Hold: 2
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the VKTX price?

Issuer Target Up/Down from current
Wallstreet Target Price 92.7 185.1%
Analysts Target Price 92.7 185.1%

VKTX Fundamental Data Overview March 29, 2026

P/B = 5.8459
P/EG = -0.03
Revenue TTM = 0.0 USD
EBIT TTM = -393.4m USD
EBITDA TTM = -393.0m USD
Long Term Debt = 137k USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 137k USD (from shortTermDebt, last quarter)
Debt = 137k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -165.7m USD (from netDebt column, last quarter)
Enterprise Value = 3.03b USD (3.74b + Debt 137k - CCE 705.7m)
Interest Coverage Ratio = -7.03k (Ebit TTM -393.4m / Interest Expense TTM 56.0k)
EV/FCF = -10.87x (Enterprise Value 3.03b / FCF TTM -278.7m)
FCF Yield = -9.20% (FCF TTM -278.7m / Enterprise Value 3.03b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 320k) / Revenue TTM)
Tobins Q-Ratio = 4.23 (Enterprise Value 3.03b / Total Assets 715.7m)
Interest Expense / Debt = 5.84% (Interest Expense 8.00k / Debt 137k)
Taxrate = 21.0% (US default 21%)
NOPAT = -310.8m (EBIT -393.4m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.33 (Total Current Assets 715.6m / Total Current Liabilities 76.7m)
Debt / Equity = 0.00 (Debt 137k / totalStockholderEquity, last quarter 639.1m)
Debt / EBITDA = 0.42 (negative EBITDA) (Net Debt -165.7m / EBITDA -393.0m)
Debt / FCF = 0.59 (negative FCF - burning cash) (Net Debt -165.7m / FCF TTM -278.7m)
Total Stockholder Equity = 748.6m (last 4 quarters mean from totalStockholderEquity)
RoA = -44.29% (Net Income -359.6m / Total Assets 715.7m)
RoE = -48.04% (Net Income TTM -359.6m / Total Stockholder Equity 748.6m)
RoCE = -52.55% (EBIT -393.4m / Capital Employed (Equity 748.6m + L.T.Debt 137k))
RoIC = -41.52% (negative operating profit) (NOPAT -310.8m / Invested Capital 748.6m)
WACC = 12.58% (E(3.74b)/V(3.74b) * Re(12.58%) + D(137k)/V(3.74b) * Rd(5.84%) * (1-Tc(0.21)))
Discount Rate = 12.58% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 6.71%
[DCF] Fair Price = unknown (Cash Flow -278.7m)
EPS Correlation: -71.51 | EPS CAGR: -64.34% | SUE: -4.0 | # QB: 0
Revenue Correlation: -2.80 | Revenue CAGR: 0.0% | SUE: 0.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=-0.98 | Chg7d=+0.000 | Chg30d=-0.005 | Revisions Net=+0 | Analysts=13
EPS current Year (2026-12-31): EPS=-4.11 | Chg7d=+0.000 | Chg30d=+0.000 | Revisions Net=-1 | Growth EPS=-29.0% | Growth Revenue=+0.0%
EPS next Year (2027-12-31): EPS=-4.57 | Chg7d=+0.000 | Chg30d=-0.528 | Revisions Net=+2 | Growth EPS=-11.1% | Growth Revenue=+0.0%
[Analyst] Revisions Ratio: +0.00 (3 Up / 3 Down within 30d for Next Quarter)

Additional Sources for VKTX Stock

Fund Manager Positions: Dataroma | Stockcircle